Using an unlevered Free Cash Flow to Firm (FCFF) model, we project ADMA Biologics, Inc.'s cash flows over 5 years with line-by-line expense modeling. Revenue is projected revenue growing from 25.0% to 11.8% annually, with expenses (COGS, SG&A, R&D) held at historical ratios. Depreciation is computed from a vintage matrix based on a 5-year useful life. Working capital is modeled using historical turnover days (DSO 72, DPO 41, DIO 418). At a 8.7% WACC with mid-year discounting, the terminal value (183% of enterprise value) is derived by applying the industry peer median EV/EBITDA multiple of 26.5x to Year 6 EBITDA. After subtracting net debt, the equity value implies a fair price of $3.40 per share, suggesting ADMA is overvalued by 56.8% at the current price of $7.88.
Adjust parameters to explore scenarios. Changes are for exploration only and do not affect saved valuations.
| 2026 | 2027 | 2028 | 2029 | 2030 | Terminal | |
|---|---|---|---|---|---|---|
| Profit Before Tax | -38 | -47 | -57 | -68 | -76 | -78 |
| (−) Net Interest | 55 | 67 | 81 | 97 | 109 | 111 |
| (+) D&A | 13 | 19 | 27 | 38 | 52 | 53 |
| EBITDA | 29 | 39 | 51 | 68 | 85 | 87 |
| (−) Tax | 0 | 0 | 0 | 0 | 0 | — |
| (−) CapEx | 43 | 53 | 64 | 77 | 86 | — |
| (−) ΔWC | 221 | 125 | 147 | 164 | 117 | — |
| Free Cash Flow (FCF) | -235 | -139 | -161 | -173 | -119 | — |
| Peers' EBITDA Multiple | 26.5x | |||||
| Terminal Value | 2,302 | |||||
| WACC / Discount Rate | 8.74% | |||||
| Timing of FCF (mid year) | 0.5 | 1.5 | 2.5 | 3.5 | 4.5 | 5 |
| Present Value of FCF | -226 | -122 | -130 | -129 | -81 | 1,514 |
| Enterprise Value | 825 | |||||
| Projection Period | -689 | -83.4% | ||||
| Terminal Value | 1,514 | 183.4% | ||||
| (−) Current Net Debt | (8) | |||||
| Equity Value | 833 | |||||
| (÷) Outstanding Shares | 245M | |||||
| Fair Price | $3 | -56.8% | ||||
| WACC \ EV/EBITDA Exit Multiple | 22.5x | 24.5x | 26.5x | 28.5x | 30.5x |
|---|---|---|---|---|---|
| 6.7% | $3 | $3 | $4 | $4 | $5 |
| 7.7% | $3 | $3 | $4 | $4 | $5 |
| 8.7% | $2 | $3 | $3 | $4 | $4 |
| 9.7% | $2 | $3 | $3 | $4 | $4 |
| 10.7% | $2 | $3 | $3 | $3 | $4 |
Current price: $7.88. Green = undervalued, Red = overvalued.
Based on default parameters
Using an unlevered Free Cash Flow to Firm (FCFF) model, we project ADMA Biologics, Inc.'s cash flows over 10 years with analyst estimates for the first 3–5 years, fading toward long-term GDP growth for the remaining years with line-by-line expense modeling. Revenue is projected revenue growing from 25.0% to 12.2% annually, with expenses (COGS, SG&A, R&D) held at historical ratios. Depreciation is computed from a vintage matrix based on a 5-year useful life. Working capital is modeled using historical turnover days (DSO 72, DPO 41, DIO 418). At a 8.7% WACC with mid-year discounting, the terminal value (286% of enterprise value) is derived by applying the industry peer median EV/EBITDA multiple of 26.5x to Year 11 EBITDA. After subtracting net debt, the equity value implies a fair price of $4.23 per share, suggesting ADMA is overvalued by 46.3% at the current price of $7.88.
Adjust parameters to explore scenarios. Changes are for exploration only and do not affect saved valuations.
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | Terminal | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit Before Tax | -38 | -47 | -57 | -68 | -76 | -99 | -128 | -167 | -203 | -227 | -233 |
| (−) Net Interest | 55 | 67 | 81 | 97 | 109 | 141 | 183 | 239 | 290 | 325 | 333 |
| (+) D&A | 13 | 19 | 27 | 38 | 52 | 65 | 78 | 97 | 122 | 152 | 156 |
| EBITDA | 29 | 39 | 51 | 68 | 85 | 107 | 134 | 169 | 209 | 250 | 257 |
| (−) Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| (−) CapEx | 43 | 53 | 64 | 77 | 86 | 112 | 145 | 189 | 230 | 258 | — |
| (−) ΔWC | 221 | 125 | 147 | 164 | 117 | 335 | 435 | 566 | 527 | 365 | — |
| Free Cash Flow (FCF) | -235 | -139 | -161 | -173 | -119 | -339 | -447 | -586 | -547 | -372 | — |
| Peers' EBITDA Multiple | 26.5x | ||||||||||
| Terminal Value | 6,796 | ||||||||||
| WACC / Discount Rate | 8.74% | ||||||||||
| Timing of FCF (mid year) | 0.5 | 1.5 | 2.5 | 3.5 | 4.5 | 5.5 | 6.5 | 7.5 | 8.5 | 9.5 | 5 |
| Present Value of FCF | -226 | -122 | -130 | -129 | -81 | -214 | -259 | -313 | -268 | -168 | 2,940 |
| Enterprise Value | 1,029 | ||||||||||
| Projection Period | -1,911 | -185.7% | |||||||||
| Terminal Value | 2,940 | 285.7% | |||||||||
| (−) Current Net Debt | (8) | ||||||||||
| Equity Value | 1,037 | ||||||||||
| (÷) Outstanding Shares | 245M | ||||||||||
| Fair Price | $4 | -46.3% | |||||||||
| WACC \ EV/EBITDA Exit Multiple | 22.5x | 24.5x | 26.5x | 28.5x | 30.5x |
|---|---|---|---|---|---|
| 6.7% | $4 | $5 | $6 | $7 | $8 |
| 7.7% | $3 | $4 | $5 | $6 | $7 |
| 8.7% | $2 | $3 | $4 | $5 | $6 |
| 9.7% | $2 | $3 | $4 | $4 | $5 |
| 10.7% | $1 | $2 | $3 | $4 | $4 |
Current price: $7.88. Green = undervalued, Red = overvalued.
Based on default parameters
Using the industry peer median P/E Multiples multiple (trailing + forward), ADMA Biologics, Inc. (ADMA) has a fair value of $19.92 based on 3 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| ADMA Biologics, Inc.ADMA | 1,930 | 13.1x | 9.3x |
| Ligand Pharmaceuticals Incorporated | 4,060 | 33.2x | 23.6x |
| ACADIA Pharmaceuticals Inc. | 3,805 | 9.7x | 49.6x |
| Soleno Therapeutics, Inc. | 2,806 | 134.0x | 13.4x |
| Industry Median | 33.2x | 23.6x | |
| (*) Profit after tax | 147 | 207 | |
| Equity Value | 4,880 | 4,875 | |
| (/) Outstanding shares | 245 | 245 | |
| Fair Price | $20 | $20 | |
Using the industry peer median EV/EBITDA multiple (trailing + forward), ADMA Biologics, Inc. (ADMA) has a fair value of $21.00 based on 3 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| ADMA Biologics, Inc.ADMA | 1,930 | 9.7x | 8.7x |
| Ligand Pharmaceuticals Incorporated | 4,060 | 22.5x | 22.6x |
| ACADIA Pharmaceuticals Inc. | 3,805 | 26.5x | 22.7x |
| Soleno Therapeutics, Inc. | 2,806 | 96.5x | 38.9x |
| Industry Median | 26.5x | 22.7x | |
| (*) EBITDA | 198 | 221 | |
| = Enterprise Value | 5,242 | 5,026 | |
| (-) Net Debt | -8 | -8 | |
| Equity Value | 5,250 | 5,034 | |
| (/) Outstanding shares | 245 | 245 | |
| Fair Price | $21 | $21 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), ADMA Biologics, Inc. (ADMA) has a fair value of $17.48 based on 5 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| ADMA Biologics, Inc.ADMA | 1,930 | 3.8x | 3.4x |
| Mirum Pharmaceuticals, Inc. | 4,831 | 9.3x | 7.5x |
| Ligand Pharmaceuticals Incorporated | 4,060 | 16.2x | 16.2x |
| ACADIA Pharmaceuticals Inc. | 3,805 | 3.4x | 2.9x |
| Soleno Therapeutics, Inc. | 2,806 | 14.4x | 5.8x |
| Ultragenyx Pharmaceutical Inc. | 2,210 | 4.5x | 4.0x |
| Industry Median | 9.3x | 5.8x | |
| (*) Revenue | 510 | 570 | |
| = Enterprise Value | 4,750 | 3,797 | |
| (-) Net Debt | -8 | -8 | |
| Equity Value | 4,758 | 3,805 | |
| (/) Outstanding shares | 245 | 245 | |
| Fair Price | $19 | $16 | |
Using the PEG framework with historical EPS growth of 8.0%, the company has a fair value of $4.80 based on TTM EPS (FY2025) of $0.60.
| EPS Growth RateHistorical | -25.9% |
| Adjusted Growth (clamped 8–25%)Clamped | 8.0% |
| Fair P/E | 8.0x |
| TTM EPS (FY2025) | $0.60 |
| Fair Value | $4.80 |
No analyst estimates available.
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-71.6M | $-0.61 | — |
| FY2022 | $-65.9M | $-0.43 | — |
| FY2023 | $-28.2M | $-0.13 | — |
| FY2024 | $197.7M | $0.81 | — |
| FY2025 | $146.9M | $0.60 | -25.9% |
4Y Historical EPS CAGR: -25.9%
Using the Earnings Power Value framework with a WACC of 8.7% and normalized earnings of $5.2M, the company has a fair value of $0.27 per share. The EPV range is $0.24 – $0.32 based on WACC sensitivity (7.2% – 10.2%).
| Low | Selected | High | |
|---|---|---|---|
| Normalized Earnings | 5 | 5 | 5 |
| (/) WACC | 10.2% | 8.7% | 7.2% |
| Enterprise Value | 50 | 59 | 71 |
| (-) Net debt | -8 | -8 | -8 |
| Equity Value | 58 | 67 | 79 |
| (/) Outstanding shares | 245 | 245 | 245 |
| Fair Price | $0.24 | $0.27 | $0.32 |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.